The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

(2014) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

The PD-1/PD-Ls pathway and autoimmune diseases

(2014) Suya Dai et al.   CELLULAR IMMUNOLOGY

Programmed death-1 pathway in cancer and autoimmunity

(2014) Ariel Pedoeem et al.   CLINICAL IMMUNOLOGY

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

(2014) Alena Gros et al.   JOURNAL OF CLINICAL INVESTIGATION

Ties That Bind: p16 As a Prognostic Biomarker and the Need for High-Accuracy Human Papillomavirus Testing

(2014) Tanguy Y. Seiwert   JOURNAL OF CLINICAL ONCOLOGY

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

MK-3475 Effective Against Melanoma

(2014)   Cancer Discovery

Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity

(2013) Elena Gianchecchi et al.   AUTOIMMUNITY REVIEWS

The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer

(2013) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity

(2013) Alan G. Ramsay   BRITISH JOURNAL OF HAEMATOLOGY

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

(2013) M. Sznol et al.   CLINICAL CANCER RESEARCH

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

(2013) B. J. Chen et al.   CLINICAL CANCER RESEARCH

Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities

(2013) Barbara Merelli et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Diagnostic and Prognostic Utility of PD-1 In B Cell Lymphomas

(2013) S. Muenst et al.   DISEASE MARKERS

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

(2013) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies

(2013) Li Shi et al.   Journal of Hematology & Oncology

At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

(2013) Andrew M. Intlekofer et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Programmed death ligand-1 expression in non-small cell lung cancer

(2013) Vamsidhar Velcheti et al.   LABORATORY INVESTIGATION

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

(2012) C. Badoual et al.   CANCER RESEARCH

Postoperative Adjuvant Chemotherapy Use in Patients With Stage II/III Rectal Cancer Treated With Neoadjuvant Therapy: A National Comprehensive Cancer Network Analysis

(2012) Polina Khrizman et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

The role of the PD-1 pathway in autoimmunity and peripheral tolerance

(2011) Brian T. Fife et al.   Annals of the New York Academy of Sciences

A frequent somatic mutation in CD274 3′-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding

(2011) Weipeng Wang et al.   HUMAN MUTATION

Progressive Upregulation of PD-1 in Primary and Metastatic Melanomas Associated with Blunted TCR Signaling in Infiltrating T Lymphocytes

(2011) Maxime Chapon et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma

(2011) Young-Ah Cho et al.   ORAL ONCOLOGY

Overall survival and PD-L1 expression in metastasized malignant melanoma

(2010) Jules Gadiot et al.   CANCER

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Costimulator B7-DC Attenuates Strong Th2 Responses Induced by Nippostrongylus brasiliensis

(2010) Kenji Ishiwata et al.   JOURNAL OF IMMUNOLOGY

Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy

(2010) Sara M. Mangsbo et al.   JOURNAL OF IMMUNOTHERAPY

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma

(2009) R. Karim et al.   CLINICAL CANCER RESEARCH

Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors

(2009) B. Li et al.   CLINICAL CANCER RESEARCH

Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival

(2009) Simone Muenst et al.   HUMAN PATHOLOGY

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells

(2009) Wenshi Wang et al.   INTERNATIONAL IMMUNOLOGY

High Numbers of Tumor-Infiltrating Programmed Cell Death 1–Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma

(2009) Joaquim Carreras et al.   JOURNAL OF CLINICAL ONCOLOGY

Human prostate-infiltrating CD8+T lymphocytes are oligoclonal and PD-1+

(2009) Karen S. Sfanos et al.   PROSTATE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

(2008) T. Azuma et al.   BLOOD

FOXP3+ Tregs and B7-H1+/PD-1+T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy

(2008) Hazem Ghebeh et al.   BMC CANCER

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH

Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia

(2008) Luc Xerri et al.   HUMAN PATHOLOGY

B7-H1 Expression in Wilms Tumor: Correlation With Tumor Biology and Disease Recurrence

(2008) Jonathan C. Routh et al.   JOURNAL OF UROLOGY

Enhancing SIV-specific immunity in vivo by PD-1 blockade

(2008) Vijayakumar Velu et al.   NATURE